Solomon Jonathan Eitan 4
4 · BiomX Inc. · Filed Oct 31, 2023
Insider Transaction Report
Form 4
BiomX Inc.PHGE
Solomon Jonathan Eitan
DirectorChief Executive Officer
Transactions
- Award
Common Stock Options - Right to Buy
2023-10-29+182,133→ 0 totalExercise: $0.28Exp: 2027-03-26→ Common Stock (0 underlying) - Disposition to Issuer
Common Stock Options - Right to Buy
2023-10-29−201,708→ 0 totalExercise: $1.97Exp: 2028-05-22→ Common Stock (0 underlying) - Award
Common Stock Options - Right to Buy
2023-10-29+201,708→ 0 totalExercise: $0.28Exp: 2028-05-22→ Common Stock (0 underlying) - Disposition to Issuer
Common Stock Options - Right to Buy
2023-10-29−284,701→ 0 totalExercise: $2.03Exp: 2029-03-29→ Common Stock (0 underlying) - Award
Common Stock Options - Right to Buy
2023-10-29+284,701→ 0 totalExercise: $0.28Exp: 2029-03-29→ Common Stock (0 underlying) - Disposition to Issuer
Common Stock Options - Right to Buy
2023-10-29−182,133→ 0 totalExercise: $1.69Exp: 2027-03-26→ Common Stock (0 underlying)
Footnotes (3)
- [F1]The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/26/2017 and provided for vesting over four years, with 25% of the shares subject to the option vested on 03/26/2018, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
- [F2]The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 05/22/2018 and provided for vesting over four years, with 25% of the shares subject to the option vesting on 05/22/2019, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.
- [F3]The reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on 03/29/2019 and provides for vesting over four years, with 25% of the shares subject to the option vested on 03/29/2020, and the remainder vested in 12 equal quarterly installments over three years; provided, however, none of the "new" options may be exercised prior to October 29, 2024.